Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M. Sun is active.

Publication


Featured researches published by M. Sun.


European Urology Supplements | 2016

93 A nationwide survey of prostate specific antigen based screening and counseling for prostate cancer

C.P. Meyer; D. Friedlander; K. Choi; A. Cole; F. Abdollah; J. Hanske; M. Zavaski; J.D. Sammon; J. Leow; Mani Menon; M. Sun; A.S. Kibel; Q-D. Trinh

Abstract Introduction Controversy surrounds prostate specific antigen screening following the 2012 U.S. Preventive Services Task Force grade D recommendation. There is limited evidence evaluating patterns of prostate specific antigen counseling and patient perceptions of the prostate specific antigen test since 2012. We evaluated the association between prostate cancer screening counseling and patient sociodemographic factors in a nationally representative sample. Methods Using data from the 2013 Health Information National Trends Survey we identified 768 male respondents age 40 to 75 years without a prior prostate cancer diagnosis. Using logistical regression we assessed trends in prostate cancer screening, counseling and prostate specific antigen use. Results Overall 54.1% of respondents reported ever having a prostate specific antigen test. Men undergoing prostate specific antigen testing were more likely to have had a prior cancer diagnosis other than prostate cancer (OR 3.93, 95% CI 1.19–12.94) and to have had at least some college education (OR 11.35, 95% CI 3.29–39.04). Men 40 to 49 years old had decreased odds of undergoing prostate specific antigen testing compared to men 50 to 69 years old (OR 0.20, 95% CI 0.10–0.39). History of cancer (OR 2.50, 95% CI 1.19–5.26) was associated with greater odds of being counseled on the potential adverse effects of prostate cancer treatment. Younger men (age 40 to 49 years) had decreased odds of discussing the prostate specific antigen test with a health care professional (OR 0.32, 95% CI 0.16–0.62) and being informed of the controversy surrounding prostate specific antigen screening (OR 0.35, 95% CI 0.13–0.95). Conclusions We show that certain men receive substantially different prostate specific antigen screening counseling, which may impact shared patient-provider decision making before prostate specific antigen counseling.


European Urology Supplements | 2016

90 Differences in prostate specific antigen testing among urologists and primary care providers in the United States following the 2011 USPSTF recommendations

C.P. Meyer; M. Zavaski; J. Hanske; D. Friedlander; P. Cheng; Mani Menon; A.S. Kibel; A. Cole; J. Leow; F. Abdollah; M. Sun; J.D. Sammon; Q-D. Trinh


European Urology Supplements | 2016

443 Minimally invasive vs open radical prostatectomy: An analysis of 30-day postoperative complications, unplanned readmissions, and mortality

C. Mever; A. Sood; F. Abdollah; J.D. Sammon; M. Vetterlein; B. Löppenberg; J. Hanske; J. Leow; A. Cole; M. Sun; Mani Menon; Q-D. Trinh


European Urology Supplements | 2016

94 Informed decision-making for prostate-specific antigen screening

N. Hanna; M. Zavaski; F. Gelpi-Hammerchmidt; C.P. Meyer; J.D. Sammon; A.S. Kibel; Mani Menon; J. Leow; M. Sun; F. Abdollah; Q-D. Trinh


European Urology Supplements | 2016

71 Morbidity, mortality and costs of treatment for locally advanced prostate cancer: A population-based analysis comparing radical prostatectomy and external beam radiation

C.P. Meyer; A.S. Feldman; A. Sanchez; G. Reznor; J. Hanske; N. Hanna; A.S. Kibel; J.D. Sammon; A. Cole; J. Leow; M. Sun; Q-D. Trinh


European Urology Supplements | 2016

669 Surgeon and hospital variation in the costs of robot-assisted radical prostatectomy in the United States

C.P. Meyer; A. Cole; J. Leow; S.L. Chang; A.S. Kibel; Mani Menon; J.D. Sammon; B. Chung; M. Sun; Q-D. Trinh


European Urology Supplements | 2016

755 Trends of metastasectomy for metastatic renal cell carcinoma and their impact on overall survival

C.P. Meyer; Q-D. Trinh; M. Vetterlein; B. Löppenberg; J. Hanske; J. Leow; J.D. Sammon; F. Abdollah; Mani Menon; A.S. Kibel; S.L. Chang; T.K. Choueiri; M. Sun


European Urology Supplements | 2015

1011 Adjuvant radiotherapy in prostate cancer patients treated with surgery: The impact of age and tumour characteristics

F. Abdollah; D.E. Klett; A. Sood; J.D. Sammon; Q-D. Trinh; F. Montorsi; A. Briganti; J.O. Peabody; Pierre I. Karakiewicz; Mani Menon; M. Sun


European Urology Supplements | 2015

638 Androgen deprivation therapy and increased non-cancer mortality in prostate cancer patients: Analysis of the number needed to harm

F. Abdollah; J.D. Sammon; A. Sood; D. Pucheril; D.E. Klett; M. Sun; A. Aizer; T.K. Choueiri; J.C. Hu; S.P. Kim; A.S. Kibel; P.L. Nguyen; Mani Menon; Q-D. Trinh


European Urology Supplements | 2015

435 Perioperative outcomes after radical cystectomy at NCI-designated centers: Are they any better?

F. Roghmann; P. Ravi; J. Hanske; C.P. Meyer; M. Schmid; M. Sun; A. Firas; J.D. Sammon; Mani Menon; A.S. Kibel; J. Noldus; Q-D. Trinh

Collaboration


Dive into the M. Sun's collaboration.

Top Co-Authors

Avatar

Q-D. Trinh

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

J.D. Sammon

Henry Ford Health System

View shared research outputs
Top Co-Authors

Avatar

J.O. Peabody

Henry Ford Health System

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge